SURMOUNT-OSA: Tirzepatide and Sleep Apnea Reversal

SURMOUNT-OSA established tirzepatide as the first drug FDA-approved for obstructive sleep apnea. Here's the trial data and what it means for OSA treatment.

SURMOUNT-OSA tested tirzepatide in patients with moderate-to-severe obstructive sleep apnea and obesity, and the results have reshaped how sleep medicine views pharmacologic intervention in OSA. Published in 2024, the two trials that make up SURMOUNT-OSA showed dramatic reductions in apnea-hypopnea index (AHI) with tirzepatide, including a substantial proportion of patients achieving disease remission.

Trial Design

SURMOUNT-OSA consisted of two phase 3 trials enrolling adults with obesity and moderate-to-severe OSA (AHI ≥15 events/hour). Study 1 included patients who were unable or unwilling to use positive airway pressure therapy; Study 2 included patients on PAP therapy. Both trials randomized participants to weekly subcutaneous tirzepatide (titrated to maximum tolerated dose, up to 15 mg) or placebo for 52 weeks. The primary endpoint was change in AHI from baseline.

Primary Results

The AHI reductions were dramatic — among the largest pharmacologic effects ever observed in OSA. The 40% disease-remission rate with tirzepatide, compared to 12% on placebo, suggests that a substantial fraction of obesity-related OSA may be functionally reversible with effective weight loss.

Weight Loss and OSA Improvement Relationship

Weight loss has long been known to improve OSA severity, but the pharmacologic weight loss produced by tirzepatide allowed a cleaner test of the relationship than was possible with bariatric surgery (which has confounding factors) or lifestyle intervention (which produces smaller weight changes). The SURMOUNT-OSA data shows a strong correlation between degree of weight loss and AHI reduction, consistent with weight being the primary mediator of the OSA benefit. Statistical analyses suggested the AHI improvement was largely but not entirely mediated by weight loss, leaving open a possibility of direct airway effects.

Quality of Life and Functional Outcomes

Beyond AHI, SURMOUNT-OSA measured patient-reported sleep quality, daytime sleepiness (Epworth Sleepiness Scale), and quality of life metrics. Tirzepatide produced meaningful improvements across these secondary endpoints, consistent with the AHI changes. Patients reported less snoring, reduced witnessed apneas, improved daytime energy, and better overall sleep experience.

The Regulatory Pathway

Based on SURMOUNT-OSA, the FDA approved an expanded indication for Zepbound in 2024 for moderate-to-severe OSA in adults with obesity. This made tirzepatide the first drug ever approved specifically for OSA — a condition historically treated mechanically with PAP therapy. The approval is important symbolically (pharmacologic OSA treatment is now an option) and practically (payers now have a path to covering tirzepatide for OSA independent of weight-management coverage policies).

PAP Therapy vs. Pharmacologic Weight Loss

PAP therapy remains the gold standard for OSA treatment because it directly prevents airway collapse during sleep and produces immediate AHI normalization. Tirzepatide is not a PAP replacement for most patients; it is an alternative for patients who cannot or will not use PAP, and an adjunctive option for patients on PAP who would benefit from the broader metabolic effects of weight loss.

Sleep medicine guidelines have begun to integrate pharmacologic weight loss into OSA treatment algorithms, with tirzepatide as the first specifically-evidence-backed option. For the broader weight-loss evidence context, see our SURMOUNT-5 fact check and STEP program review.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.